docetaxel anhydrous has been researched along with u-104 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (u-104) | Trials (u-104) | Recent Studies (post-2010) (u-104) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 58 | 1 | 55 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreucci, E; Antonuzzo, L; Biagioni, A; Bianchini, F; Calorini, L; Cianchi, F; Lulli, M; Magnelli, L; Massi, D; Messerini, L; Olivo, E; Papucci, L; Pasqualini, E; Peppicelli, S; Peri, S; Ruzzolini, J; Schiavone, N; Staderini, F; Supuran, CT; Versienti, G | 1 |
1 other study(ies) available for docetaxel anhydrous and u-104
| Article | Year |
|---|---|
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line; Cell Line, Tumor; Docetaxel; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Stomach Neoplasms; Taxoids | 2023 |